Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl buccal - Teva

Drug Profile

Fentanyl buccal - Teva

Alternative Names: E-fen buccal tablets; Effentora; Fentanyl buccal - Cephalon; Fentanyl citrate - Teva; Fentora; OraVescent® fentanyl; OVF

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CIMA LABS
  • Developer BMP Sunstone Corporation; CIMA LABS; M. D. Anderson Cancer Center; Taiho Pharmaceutical; Teva Pharmaceutical Industries
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain
  • Phase II Dyspnoea
  • Preregistration Submission Withdrawal Pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 02 Aug 2019 Phase II development is still ongoing for Dyspnoea USA (NCT01856114)
  • 02 Aug 2019 No development reported - Phase-II for Dyspnoea in Germany (Buccal) (EudraCT2011-005797-32)
  • 06 Jun 2017 Efficacy data from a phase II trial in Dyspnoea (in cancer patients) reported at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top